These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28808351)

  • 1. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
    Abdullah MI; Abed MN; Richardson A
    Sci Rep; 2017 Aug; 7(1):8090. PubMed ID: 28808351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
    Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
    BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    Göbel A; Zinna VM; Dell'Endice S; Jaschke N; Kuhlmann JD; Wimberger P; Rachner TD
    BMC Cancer; 2020 Jul; 20(1):703. PubMed ID: 32727400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.
    de Wolf E; Abdullah MI; Jones SM; Menezes K; Moss DM; Drijfhout FP; Hart SR; Hoskins C; Stronach EA; Richardson A
    Sci Rep; 2017 Jul; 7(1):5410. PubMed ID: 28710496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
    Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
    Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death.
    Abdullah MI; Abed MN; Khanim F; Richardson A
    Sci Rep; 2019 Jul; 9(1):9632. PubMed ID: 31270377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells.
    Jawad MJ; Richardson A
    Diseases; 2023 Mar; 11(1):. PubMed ID: 36975598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of statins as a treatment for ovarian cancer.
    Robinson E; Nandi M; Wilkinson LL; Arrowsmith DM; Curtis AD; Richardson A
    Gynecol Oncol; 2013 May; 129(2):417-24. PubMed ID: 23402903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of foods that affect the anti-cancer activity of pitavastatin in cells.
    Jawad MJ; Ibrahim S; Kumar M; Burgert C; Li WW; Richardson A
    Oncol Lett; 2022 Mar; 23(3):73. PubMed ID: 35111242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
    BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.
    Zafar S; Coates DE; Cullinan MP; Drummond BK; Milne T; Seymour GJ
    J Oral Pathol Med; 2014 Oct; 43(9):711-21. PubMed ID: 24762323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
    Li YY; Chang JW; Liu YC; Wang CH; Chang HJ; Tsai MC; Su SP; Yeh KY
    Anticancer Drugs; 2011 Jan; 22(1):89-98. PubMed ID: 20926944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
    Witters LM; Crispino J; Fraterrigo T; Green J; Lipton A
    Am J Clin Oncol; 2003 Aug; 26(4):S92-7. PubMed ID: 12902864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.
    Kobayashi Y; Kashima H; Wu RC; Jung JG; Kuan JC; Gu J; Xuan J; Sokoll L; Visvanathan K; Shih IeM; Wang TL
    Clin Cancer Res; 2015 Oct; 21(20):4652-62. PubMed ID: 26109099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
    Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.